FindTrial
Sign In

A Clinical Trail of Venkara Parpam for Neerkattu Vatham (Benign Prostatic Hyperplasia)

An Open Non Randomized Single Arm, Single Centric Clinical Trial To Determine The Effectiveness Of Venkara Parpam In The Management Of Neerkattu Vatham (Benign Prostatic Hyperplasia) Among Out Patients Attending Ayothidoss Pandithar Hospital, National Institute Of Siddha

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/07/044050
Enrollment
25
Registered
2022-07-15
Start date
Unknown
Completion date
Unknown
Last updated
2022-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N401- Benign prostatic hyperplasia withlower urinary tract symptoms

Interventions

Intervention1: Venkara Parpam: 500 mg with Tender coconut water BD After food for 48 days Control Intervention1: NIL: NIL

Sponsors

National Institute of Siddha
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients having symptoms such as delay in initiating micturition,hesitancy,weak urinary stream,straining to void,sensation of incomplete emptying and terminal dribbling. 2. Increased residual urine volume 3. Nocturia ,urgency,bladder pain, dysuria 4. PSA (Prostate specific antigen) less than 10ng/ml. 5. USG prostate volume not more than 80 cc

Exclusion criteria

Exclusion criteria: KNOWN CASE OF CA prostate Urinary bladder calculus Acute and chronic renal failure Diabetic nephropathy Stricture urethra PSA more than 10 ng/ml USG prostate volume more than 80ml

Design outcomes

Primary

MeasureTime frame
Assessment by clinical symptoms using IPSS assessing scale.Timepoint: Screening - 2 months Enrolment - 2 months Drug - 4 months Data analysis - 2 months Follow up - 2 months—

Secondary

MeasureTime frame
1. To assess the changes in PSA Level 2. To assess the reduction in size of the prostrate gland and prostrate volume and residual urine volume using ultrasound scan.Timepoint: Screening - 2 months Enrolment - 2 months Drug - 4 months Data analysis - 2 months Follow up - 2 months—

Countries

India

Contacts

Public ContactDr T Lakshmikantham MDS PhD

National Institute of Siddha

drlakshmiramaswamy@gmail.com9444466880

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026